Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040
Issued Date
2024-01-01
Resource Type
ISSN
00256196
eISSN
19425546
Scopus ID
2-s2.0-85188992825
Journal Title
Mayo Clinic Proceedings
Rights Holder(s)
SCOPUS
Bibliographic Citation
Mayo Clinic Proceedings (2024)
Suggested Citation
Danpanichkul P., Ng C.H., Muthiah M.D., Duangsonk K., Kongarin S., Srisurapanont K., Pingwang P., Songmueang N., Nonthasoot C., Manosroi W., Nathisuwan S., Li F., Yang J.D., Chen V.L., Kim D., Noureddin M., Huang D.Q., Wijarnpreecha K. Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040. Mayo Clinic Proceedings (2024). doi:10.1016/j.mayocp.2023.12.025 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97885
Title
Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040
Author's Affiliation
National University Health System
University of Michigan Medical School
Faculty of Medicine, Chiang Mai University
University of Texas Health Science Center at Houston
NUS Yong Loo Lin School of Medicine
Cedars-Sinai Medical Center
Houston Methodist Hospital
Mahidol University
University of Arizona College of Medicine – Phoenix
Banner - University Medical Center Phoenix
Chiang Mai University
University of Michigan Medical School
Faculty of Medicine, Chiang Mai University
University of Texas Health Science Center at Houston
NUS Yong Loo Lin School of Medicine
Cedars-Sinai Medical Center
Houston Methodist Hospital
Mahidol University
University of Arizona College of Medicine – Phoenix
Banner - University Medical Center Phoenix
Chiang Mai University
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: To quantify the burden of metabolic dysfunction–associated steatotic liver disease (MASLD) and related metabolic disorders in premenopausal women. Patients and Methods: Between 2010 and 2019, global evaluations of prevalence, mortality, disability-adjusted life years (DALYs), and their age-standardized rate (ASR) were conducted for metabolic conditions such as MASLD, type 2 diabetes mellitus, dyslipidemia, hypertension (HTN), obesity, and polycystic ovarian syndrome. Subgroup assessments were conducted according to geographical regions and the sociodemographic index. The predictive models were established to estimate mortality and DALYs through 2040. Results: In 2019, the most significant ASR of deaths was found in HTN (11.37; 9.52 to 13.45), followed by obesity (10.49; 7.57 to 13.64). In contrast, the greatest ASR of DALYs was attributed to obesity (816.13; 581.41 to 1073.32), followed by HTN (634.73; 536.75 to 744.77). The mortality rates for dyslipidemia (–0.55%) and HTN (–0.72%) have been decreasing over time, but there has been an increase in obesity (+0.58%), type 2 diabetes mellitus (+0.85%), and MASLD (+0.51%). Lower sociodemographic index countries exhibit a higher disability-to-prevalence ratio. In 2040, obesity is predicted to cause the most deaths (+41.59% from 2019). Conclusion: The escalating impact of metabolic syndrome, the rising trends in death rates linked to obesity, and the disparities based on region and socioeconomic status in premenopausal women underscore the alarming increase in the global burden of metabolic syndrome.